|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Downward GS, Hu W, Large D, Veld H, Xu J,
Reiss B, Wu G, Wei F, Chapman RS, Rothman N, et al: Heterogeneity
in coal composition and implications for lung cancer risk in
Xuanwei and Fuyuan counties, China. Environ Int. 68:94–104. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu ZY, He XZ and Chapman RS: Smoking and
other risk factors for lung cancer in Xuanwei, China. Int J
Epidemiol. 20:26–31. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shen M, Chapman RS, He X, Liu LZ, Lai H,
Chen W and Lan Q: Dietary factors, food contamination and lung
cancer risk in Xuanwei, China. Lung Cancer. 61:275–282. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lan Q, Chapman RS, Schreinemachers DM,
Tian L and He X: Household stove improvement and risk of lung
cancer in Xuanwei, China. J Natl Cancer Inst. 94:826–835. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim C, Chapman RS, Hu W, He X, Hosgood HD,
Liu LZ, Lai H, Chen W, Silverman DT, Vermeulen R, et al: Smoky
coal, tobacco smoking, and lung cancer risk in Xuanwei, China. Lung
Cancer. 84:31–35. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Reed E: ERCC1 and clinical resistance to
platinum-based therapy. Clin Cancer Res. 11:6100–6102. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sodja E, Knez L, Kern I, Ovčariček T,
Sadikov A and Cufer T: Impact of ERCC1 expression on treatment
outcome in small-cell lung cancer patients treated with
platinum-based chemotherapy. Eur J Cancer. 48:3378–3385. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Siddik ZH: Cisplatin: Mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Martin LP, Hamilton TC and Schilder RJ:
Platinum resistance: The role of DNA repair pathways. Clin Cancer
Res. 14:1291–1295. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zamble DB, Mu D, Reardon JT, Sancar A and
Lippard SJ: Repair of cisplatin - DNA adducts by the mammalian
excision nuclease. Biochemistry. 35:10004–10013. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Selby CP and Sancar A: Mechanisms of
transcription-repair coupling and mutation frequency decline.
Microbiol Rev. 58:317–329. 1994.PubMed/NCBI
|
|
13
|
Mu D, Hsu DS and Sancar A: Reaction
mechanism of human DNA repair excision nuclease. J Biol Chem.
271:8285–8294. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Smith S, Su D, de la Rigault Longrais IA,
Schwartz P, Puopolo M, Rutherford TJ, Mor G, Yu H and Katsaros D:
ERCC1 genotype and phenotype in epithelial ovarian cancer identify
patients likely to benefit from paclitaxel treatment in addition to
platinum-based therapy. J Clin Oncol. 25:5172–5179. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Krivak TC, Darcy KM, Tian C, Armstrong D,
Baysal BE, Gallion H, Ambrosone CB and DeLoia JA: Gynecologic
Oncology Group Phase III Trial: Relationship between ERCC1
polymorphisms, disease progression, and survival in the Gynecologic
Oncology Group Phase III Trial of intraperitoneal versus
intravenous cisplatin and paclitaxel for stage III epithelial
ovarian cancer. J Clin Oncol. 26:3598–3606. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yamada Y, Boku N, Nishina T, Yamaguchi K,
Denda T, Tsuji A, Hamamoto Y, Konishi K, Tsuji Y, Amagai K, et al:
Impact of excision repair cross-complementing gene 1 (ERCC1) on the
outcomes of patients with advanced gastric cancer: Correlative
study in Japan Clinical Oncology Group Trial JCOG9912. Ann Oncol.
24:2560–2565. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Squires MH III, Fisher SB, Fisher KE,
Patel SH, Kooby DA, El-Rayes BF, Staley CA III, Farris AB III and
Maithel SK: Differential expression and prognostic value of ERCC1
and thymidylate synthase in resected gastric adenocarcinoma.
Cancer. 119:3242–3250. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kuhlmann JD, Wimberger P, Bankfalvi A,
Keller T, Schöler S, Aktas B, Buderath P, Hauch S, Otterbach F,
Kimmig R, et al: ERCC1-positive circulating tumor cells in the
blood of ovarian cancer patients as a predictive biomarker for
platinum resistance. Clin Chem. 60:1282–1289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hatch SB, Swift LP, Caporali S, Carter R,
Hill EJ, MacGregor TP, D'Atri S, Middleton MR, McHugh PJ and Sharma
RA: XPF protein levels determine sensitivity of malignant melanoma
cells to oxaliplatin chemotherapy: Suitability as a biomarker for
patient selection. Int J Cancer. 134:1495–1503. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bauman JE, Austin MC, Schmidt R, Kurland
BF, Vaezi A, Hayes DN, Mendez E, Parvathaneni U, Chai X, Sampath S,
et al: ERCC1 is a prognostic biomarker in locally advanced head and
neck cancer: Results from a randomised, phase II trial. Br J
Cancer. 109:2096–2105. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cecere F, Bria E and Rosell R: DNA repair
by ERCC1 in non-small-cell lung cancer. N Engl J Med.
355:2590–2591; author reply 2591. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bepler G, Williams C, Schell MJ, Chen W,
Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, et al:
Randomized international phase III trial of ERCC1 and RRM1
expression-based chemotherapy versus gemcitabine/carboplatin in
advanced non-small-cell lung cancer. J Clin Oncol. 31:2404–2412.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Soria JC: ERCC1-tailored chemotherapy in
lung cancer: The first prospective randomized trial. J Clin Oncol.
25:2648–2649. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shiraishi K, Kohno T, Tanai C, Goto Y,
Kuchiba A, Yamamoto S, Tsuta K, Nokihara H, Yamamoto N, Sekine I,
et al: Association of DNA repair gene polymorphisms with response
to platinum-based doublet chemotherapy in patients with
non-small-cell lung cancer. J Clin Oncol. 28:4945–4952. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Weiwei W, Zaoxiu H, Deguang W and Yong Z:
Comparison of ERCC1 expression in lung adenoma tissue from Xuanwei
of Yunnan province and other areas. Shangdong Med. 22:67–68.
2016.
|
|
26
|
Rubatt JM, Darcy KM, Tian C, Muggia F,
Dhir R, Armstrong DK, Bookman MA, Niedernhofer LJ, Deloia J, Birrer
M, et al: Pre-treatment tumor expression of ERCC1 in women with
advanced stage epithelial ovarian cancer is not predictive of
clinical outcomes: A Gynecologic Oncology Group study. Gynecol
Oncol. 125:421–426. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Olaussen KA, Dunant A, Fouret P, Brambilla
E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH,
et al: IALT Bio Investigators: DNA repair by ERCC1 in
non-small-cell lung cancer and cisplatin-based adjuvant
chemotherapy. N Engl J Med. 355:983–991. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang X, Zhao J, Yang L, Mao L, An T, Bai
H, Wang S, Liu X, Feng G and Wang J: Positive expression of ERCC1
predicts a poorer platinum-based treatment outcome in Chinese
patients with advanced non-small-cell lung cancer. Med Oncol.
27:484–490. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ota S, Ishii G, Goto K, Kubota K, Kim YH,
Kojika M, Murata Y, Yamazaki M, Nishiwaki Y, Eguchi K, et al:
Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen
predicts survival in advanced non-small-cell lung cancer treated
with cisplatin-based chemotherapy. Lung Cancer. 64:98–104. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee HW, Choi YW, Han JH, Kim JH, Jung JH,
Jeong SH, Kang SY, Choi JH, Oh YT, Park KJ, et al: Expression of
excision repair cross-complementation group 1 protein predicts poor
outcome in advanced non-small cell lung cancer patients treated
with platinum-based doublet chemotherapy. Lung Cancer. 65:377–382.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Holm B, Mellemgaard A, Skov T and Skov BG:
Different impact of excision repair cross-complementation group 1
on survival in male and female patients with inoperable
non-small-cell lung cancer treated with carboplatin and
gemcitabine. J Clin Oncol. 27:4254–4259. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Azuma K, Komohara Y, Sasada T, Terazaki Y,
Ikeda J, Hoshino T, Itoh K, Yamada A and Aizawa H: Excision repair
cross-complementation group 1 predicts progression-free and overall
survival in non-small cell lung cancer patients treated with
platinum-based chemotherapy. Cancer Sci. 98:1336–1343. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yu D, Zhang X, Liu J, Yuan P, Tan W, Guo
Y, Sun T, Zhao D, Yang M, Liu J, et al: Characterization of
functional excision repair cross-complementation group 1 variants
and their association with lung cancer risk and prognosis. Clin
Cancer Res. 14:2878–2886. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Snyder A, Makarov V, Merghoub T, Yuan J,
Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, et
al: Genetic basis for clinical response to CTLA-4 blockade in
melanoma. N Engl J Med. 371:2189–2199. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rizvi NA, Hellmann MD, Snyder A, Kvistborg
P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al: Cancer
immunology. Mutational landscape determines sensitivity to PD-1
blockade in non-small cell lung cancer. Science. 348:124–128. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Simon GR, Sharma S, Cantor A, Smith P and
Bepler G: ERCC1 expression is a predictor of survival in resected
patients with non-small cell lung cancer. Chest. 127:978–983. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Schneider JG, Farhadfar N, Sivapiragasam
A, Geller M, Islam S and Selbs E: Commercial laboratory testing of
excision repair cross-complementation group 1 expression in
non-small cell lung cancer. Oncologist. 19:459–465. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cheng H, Zhang Z, Rodriguez-Barrueco R,
Borczuk A, Liu H, Yu J, Silva JM, Cheng SK, Perez-Soler R and
Halmos B: Functional genomics screen identifies YAP1 as a key
determinant to enhance treatment sensitivity in lung cancer cells.
Oncotarget. 7:28976–28988. 2016.PubMed/NCBI
|
|
39
|
Jiang P, Wu X, Wang X, Huang W and Feng Q:
NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin
sensitivity in lung cancer cells. Oncotarget. 7:43337–43351.
2016.PubMed/NCBI
|
|
40
|
Reed E: Nucleotide excision repair and
anti-cancer chemotherapy. Cytotechnology. 27:187–201. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Olaussen KA and Postel-Vinay S: Predictors
of chemotherapy efficacy in non-small-cell lung cancer: A
challenging landscape. Ann Oncol. 27:2004–2016. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cobo M, Isla D, Massuti B, Montes A,
Sanchez JM, Provencio M, Viñolas N, Paz-Ares L, Lopez-Vivanco G,
Muñoz MA, et al: Customizing cisplatin based on quantitative
excision repair cross-complementing 1 mRNA expression: A phase III
trial in non-small-cell lung cancer. J Clin Oncol. 25:2747–2754.
2007. View Article : Google Scholar : PubMed/NCBI
|
